Nuochengjianhua announced today that clinical research on soficitinib, a novel TYK2 inhibitor independently developed by the company, has made significant progress. The Phase III registered clinical trial for the treatment of moderate to severe atopic dermatitis has completed patient enrollment, marking a critical step for soficitinib in addressing AD disease. At the same time, the phase II clinical trial of soficitinib to treat vitiligo has also completed patient enrollment.

Nuochengjianhua announced today that clinical research on soficitinib, a novel TYK2 inhibitor independently developed by the company, has made significant progress. The Phase III registered clinical trial for the treatment of moderate to severe atopic dermatitis has completed patient enrollment, marking a critical step for soficitinib in addressing AD disease. At the same time, the phase II clinical trial of soficitinib to treat vitiligo has also completed patient enrollment.